Sirolimus-Based Immunosuppression Therapy in OLT for Patients With HCC Exceeding Milan Criteria

NCT00554125 · clinicaltrials.gov ↗
PHASE3
Phase
UNKNOWN
Status
220
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Fudan University